🫁 New ALK option: Nelkarmi approved for treated NSCLC
🫁 New ALK option: Nelkarmi approved for treated NSCLC
GSK won accelerated FDA approval for Nelkarmi (neladalkib) in previously treated ALK-positive NSCLC, backed by the single-arm Phase I/II ALKOVE-1 trial: confirmed ORR was 49% in 67 patients after alectinib only, and 32% in 155 patients after at least two prior ALK TKIs plus platinum chemotherapy. Among patients with measurable CNS metastases at baseline, intracranial ORR was 55% and 26%, respectively, underscoring activity in a key unmet-need population.
Why It Matters To Oncology
Nelkarmi adds a new post-TKI option for ALK-positive NSCLC, a molecular subset where resistance mutations and CNS progression commonly drive treatment failure.
The label covers adults with unresectable locally advanced or metastatic disease who either received alectinib as their only prior ALK TKI, or at least two prior ALK TKIs plus platinum-based chemotherapy.
GSK says the drug was designed for broad ALK resistance coverage, blood-brain barrier penetration and high selectivity — features that matter for durability and tolerability in a typically younger patient population.
The Financials
The approval marks GSK's second FDA nod from its $10.6 billion Nuvalent acquisition, which closed four months ago.
It follows July's approval of Jideytro (zidesamtinib) for ROS1-positive NSCLC, completing regulatory review of the two late-stage lung cancer assets acquired in the deal.
The transaction also brought earlier-stage HER2-selective TKI NVL-330 into GSK's oncology pipeline.
What They're Saying
GSK CSO Tony Wood said Nelkarmi was designed to address key challenges in ALK-positive NSCLC through broad resistance-mutation coverage, CNS penetration and target selectivity.
Wood added that ALK-positive patients are often younger and may stay on therapy for years, making effective and tolerable new options especially important.
Safety will be part of the clinical conversation: common adverse reactions included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, oedema and fatigue.
What's Next
Because this is an accelerated approval, confirmatory evidence will be important to define Nelkarmi's long-term place in the ALK treatment sequence.
Clinicians will watch how the drug performs in practice for CNS disease control, duration of response and use after specific prior ALK inhibitors.
Label warnings include hepatotoxicity, renal and ocular toxicity, elevated creatine phosphokinase and embryo-foetal toxicity; 5% of patients permanently discontinued therapy because of adverse reactions, most often hepatotoxicity.
Reference: GSK's Nuvalent takeout brings another lung cancer drug to market